# Lucid Diagnostics Inc.: overview

LUCD · Nasdaq · CIK 1799011 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lucd.md) · [Financials](/companies/lucd/financials.md) · [Filings](/companies/lucd/filings.md) · [Insiders](/companies/lucd/insiders.md)

Latest reported revenue: [$1.5m](/filings/0001437749-26-027335.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-027335).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.2](/filings/0001493152-25-021737.md) | [1.2 d](/filings/0001641172-25-000205.md) | [0.8](/filings/0001641172-25-009986.md) | [1.2](/filings/0001493152-25-011862.md) | [1.2](/filings/0001493152-25-021737.md) | [1.5 d](/filings/0001437749-26-009805.md) | [1.3](/filings/0001437749-26-016751.md) | [1.5](/filings/0001437749-26-027335.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(997.8%)](/filings/0001493152-25-021737.md) | [(1033.8%) d](/filings/0001437749-26-009805.md) | [(1508.1%)](/filings/0001437749-26-016751.md) | [(978.8%)](/filings/0001437749-26-027335.md) | [(971.0%)](/filings/0001493152-25-021737.md) | [(931.6%) d](/filings/0001437749-26-009805.md) | [(964.5%)](/filings/0001437749-26-016751.md) | [(868.5%)](/filings/0001437749-26-027335.md) |
| Net margin | % | [(1055.5%)](/filings/0001493152-25-021737.md) | [(964.2%) d](/filings/0001437749-26-009805.md) | [(3249.8%)](/filings/0001437749-26-016751.md) | [(381.7%)](/filings/0001437749-26-027335.md) | [(858.5%)](/filings/0001493152-25-021737.md) | [(1081.5%) d](/filings/0001437749-26-009805.md) | [(1107.4%)](/filings/0001437749-26-016751.md) | [(792.9%)](/filings/0001437749-26-027335.md) |
| Diluted EPS | $ per share | [(0.25)](/filings/0001493152-25-021737.md) | not reported | [(0.52)](/filings/0001641172-25-009986.md) | [(0.08)](/filings/0001493152-25-011862.md) | [(0.10)](/filings/0001493152-25-021737.md) | not reported | not reported | not reported |
| Free cash flow | $m | not reported | not reported | [(12.6)](/filings/0001437749-26-016751.md) | [(10.6) d](/filings/0001437749-26-027335.md) | not reported | not reported | [(12.3)](/filings/0001437749-26-016751.md) | [(11.3) d](/filings/0001437749-26-027335.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.5](/filings/0001493152-23-007482.md) | [0.4](/filings/0001493152-24-011161.md) | [2.4](/filings/0001641172-25-000205.md) | [4.3](/filings/0001641172-25-000205.md) | [4.7](/filings/0001437749-26-009805.md) |
| Gross margin | % | [100.0%](/filings/0001493152-23-007482.md) | [100.0%](/filings/0001493152-23-007482.md) | not reported | not reported | not reported |
| Operating margin | % | [(5483.8%)](/filings/0001493152-23-007482.md) | [(14920.7%)](/filings/0001493152-24-011161.md) | [(1996.8%)](/filings/0001641172-25-000205.md) | [(1059.6%)](/filings/0001437749-26-009805.md) | [(1054.8%)](/filings/0001437749-26-009805.md) |
| Net margin | % | [(5615.6%)](/filings/0001493152-23-007482.md) | [(14899.5%)](/filings/0001493152-24-011161.md) | [(2169.1%)](/filings/0001641172-25-000205.md) | [(1047.6%)](/filings/0001437749-26-009805.md) | [(1232.7%)](/filings/0001437749-26-009805.md) |
| Diluted EPS | $ per share | [(1.51)](/filings/0001493152-22-009199.md) | [(1.55)](/filings/0001493152-24-011161.md) | [(1.26)](/filings/0001641172-25-000205.md) | [(1.05)](/filings/0001641172-25-000205.md) | not reported |
| Free cash flow | $m | [(18.5)](/filings/0001493152-23-007482.md) | [(32.9)](/filings/0001493152-24-011161.md) | not reported | [(44.4)](/filings/0001437749-26-009805.md) | [(46.7)](/filings/0001437749-26-009805.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/lucd/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2021-10-18 | [PAVmed Inc.](/insiders/1624326.md) | 10% owner | Purchase (P) | 571,428 | $14.00 | $8.0m | [Form 4](/filings/0001062993-21-009743.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $9.5m | 8,856,844 |  | New +8,856,844 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $9.0m | 8,373,117 |  | Added +3,734,874 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.0m | 6,556,344 |  | Added +2,401,574 |
| [Two Seas Capital LP](/funds/1823138.md) | 2026-06-30 | $6.4m | 6,000,000 |  | Added +3,000,000 |
| [MASTERS CAPITAL MANAGEMENT LLC](/funds/1104186.md) | 2026-06-30 | $4.3m | 4,000,000 |  | Unchanged |
| [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $4.1m | 3,822,997 |  | Added +178,720 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $4.1m | 3,789,948 |  | Added +1,544,598 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.6m | 2,437,337 |  | Added +882,756 |
| [FIRST MANHATTAN CO. LLC.](/funds/728083.md) | 2026-06-30 | $2.3m | 2,188,550 |  | Added +1,865,100 |
| [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $2.2m | 2,067,046 |  | Added +792,656 |

## Recent filings

[All 281 filings](/companies/lucd/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-22 | 20:34 ET | [8-K](/filings/0001493152-26-048114.md) | 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-048114 |
| 2026-10-16 | 20:30 ET | [8-K](/filings/0001493152-26-047404.md) | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001493152-26-047404 |
| 2026-09-22 | 13:06 ET | [8-K](/filings/0001493152-26-043659.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-043659 |
| 2026-08-13 | 12:23 ET | [8-K](/filings/0001493152-26-037596.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-037596 |
| 2026-08-12 | 20:30 ET | [10-Q](/filings/0001437749-26-027335.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027335 |
| 2026-06-24 | 21:00 ET | [8-K](/filings/0001493152-26-029943.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-029943 |
| 2026-05-14 | 12:05 ET | [8-K](/filings/0001493152-26-022877.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-022877 |
| 2026-05-13 | 20:31 ET | [10-Q](/filings/0001437749-26-016751.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016751 |
| 2026-04-30 | 21:00 ET | [DEF 14A](/filings/0001493152-26-020708.md) | Proxy statement, period 2026-04-30 | 0001493152-26-020708 |
| 2026-04-24 | 20:30 ET | [8-K](/filings/0001493152-26-018926.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-018926 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009805.md), filed Mar 25, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0559dd3f-580a-4041-bbd4-b9dfd9924b52)

## About the filer

- CIK: 1799011
- Tickers: LUCD
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.